Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom

Table 6

Base-case results for pairwise indirect comparisons versus pazopanib (PPS-based analysis).

	Pazopanib^a	Trabectedin	Ifosfamide	Gemcitabine; + docetaxel	Pazopanib versus trabectedin	Pazopanib versus ifosfamide	Pazopanib versus gemcitabine; + docetaxel
Effectiveness (discounted)
LYs	1.375	1.334	1.336	1.373	0.041	0.039	0.003
PFLYs	0.503	0.461	0.463	0.500	0.042	0.040	0.003
PPLYs	0.872	0.874	0.873	0.872	−0.001	−0.001	0.000
QALYs	0.692	0.663	0.652	0.691	0.029	0.040	0.001
Costs (discounted), £
Study medication	10,733	11,699	5,675	9,769	−965	5,059	964
Administration	81	2,491	6,516	2,707	−2,411	−6,435	−2,627
Adverse events	653	3,481	2,706	1,685	−2,828	−2,053	−1,033
Other costs PFS	557	1,080	1,082	554	−522	−525	3
Other costs PPS	10,464	10,466	10,466	10,464	−3	−3	0
Total	22,488	29,217	26,445	25,180	−6,729	−3,957	−2,692
Cost per QALY gained					Dominant	Dominant	Dominant

LYs: life-years; PFLYs: progression-free life-years; PFS: progression-free survival; PPLYs: postprogression life-years; PPS: postprogression survival; QALYs: quality-adjusted life-years.
aBecause a Markov methodology was used for the indirect comparison, the effectiveness and cost results are similar but not identical to the direct comparison with placebo.